Business & Finance
US government buys 388,000 additional doses of Eli Lilly's COVID-19 antibody therapy
15 September 2021 -

The US government has purchased 388,000 additional doses of US pharmaceutical company Eli Lilly and Company's (Lilly) (NYSE:LLY) COVID-19 antibody therapy, Reuters news agency reported on Wednesday.

According to the company, it will supply additional doses of etesevimab to be paired with doses of its other COVID-19 antibody therapy, bamlanivimab, previously purchased by the US government.

Bamlanivimab and etesevimab are authorised for use in people 12 years and above with mild-to-moderate infection and at high risk for progression to severe COVID-19.

Lilly said its deal with the US government is expected to generate approximately USD330m in revenues in the second half of 2021, with about 200,000 doses expected to be shipped in the third quarter this year and the remaining in the fourth.